Salesi Mansour, Shojaie Behrokh, Naderi Zohre
Department of Internal Medicine, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran.
Acquired Immunodeficiency Research Center, Isfahan University of Medical Sciences, Isfahan, Iran.
Adv Biomed Res. 2021 Sep 29;10:25. doi: 10.4103/abr.abr_266_20. eCollection 2021.
The COVID-19 pandemic has raised concerns among physicians and patients with autoimmune disorders about how this viral infection affects the patients receiving immunosuppressive drugs. There are speculations about a higher incidence and severity of COVID-19 in patients receiving a variety of immunosuppressant drugs. However, we reported the rapid recovery from COVID-19 in a 67-year-old male with granulomatosis with polyangiitis who did not experience severe symptoms of the COVID-19 as expected, despite having a history of serious lung involvement due to the autoimmune disease. He received conventional medications to treat COVID-19, though he had been receiving rituximab and corticosteroids before the onset of COVID-19 symptoms. Prevention of the cytokine storm caused by SARS-CoV-2 infection owing to taking the immunosuppressive drugs (rituximab and corticosteroids) could be a reason for these unexpected observations. Therefore, this case showed that taking immunosuppressive drugs is unlikely to be directly related to the increased severity of COVID-19.
新型冠状病毒肺炎(COVID-19)大流行引发了自身免疫性疾病患者及其医生对这种病毒感染如何影响接受免疫抑制药物治疗患者的担忧。有推测称,接受各种免疫抑制药物治疗的患者感染COVID-19的发生率和严重程度更高。然而,我们报告了一名67岁患有肉芽肿性多血管炎的男性患者从COVID-19中迅速康复的情况,尽管他因自身免疫性疾病有严重肺部受累史,但并未如预期那样出现COVID-19的严重症状。他接受了治疗COVID-19的常规药物,尽管在出现COVID-19症状之前他一直在接受利妥昔单抗和皮质类固醇治疗。服用免疫抑制药物(利妥昔单抗和皮质类固醇)预防由严重急性呼吸综合征冠状病毒2(SARS-CoV-2)感染引起的细胞因子风暴可能是这些意外观察结果的一个原因。因此,该病例表明,服用免疫抑制药物不太可能与COVID-19严重程度增加直接相关。